
Drug-eluting stents (DES) were associated with decreased rates of death, myocardial infarction (MI), and revascularization at 3 years of follow up in diabetic patients compared to bare-metal stents (BMS), according to results of a large observational study. “Our primary concern was to look at safety,” says Laura Mauri, MD (pictured) Brigham and Women’s Hospital and Harvard Medical School, Boston. “Considering the safety concerns surrounding DES recently, it was to our surprise that we found a significant difference in the opposite direction.















































































































































